NMRA
Neumora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.73
−2.67%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.19
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.23
- EPS estimate
- -$0.24
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +5.2%
- Revenue beats (12Q)
- —
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.24 | -$0.23 | Beat 4.20% | — |
| May 7, 2026 | -$0.32 | -$0.30 | Beat 6.25% | — |
| Nov 6, 2025 | -$0.34 | -$0.35 | Miss -2.94% | — |
| Aug 6, 2025 | -$0.38 | -$0.33 | Beat 13.16% | — |
| Mar 3, 2025 | -$0.46 | -$0.37 | Beat 19.57% | — |
| Mar 7, 2024 | -$0.65 | -$0.71 | Miss -9.23% | — |
| Nov 1, 2023 | -$0.36 | -$1.14 | Miss -216.67% | — |
| Sep 29, 2022 | — | -$0.19 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026